eligible ages (years): 18.0-999.0,  All  Malignant Neoplasm of Lung A soft tissue solitary dominant pulmonary nodule of ≥ 8mm and ≤30mm on axial plane Measured on lung window using conventional CT scan No other ancillary evidence strongly indicative of malignancy (e.g. distant metastases or unequivocal local invasion) If clinicians and reporting radiologists believe the patient is being treated as having a single pulmonary nodule and there are other small lesions <4mm that would normally be disregarded, the patient should be included in the trial Nodules already under surveillance can be included provided they have a recent or scheduled FDG-PET/CT18 years of age or over at time of providing consent Able and willing to consent to study  Pregnancy History of malignancy within the past 2 years Confirmed aetiology of the nodule at the time of qualifying CT scan As this is a diagnostic study, should the aetiology of the nodule be confirmed by investigation such as FDG-PET/CT or bronchoscopy prior to consent the patient remains eligible as the intention to is made on the analysis of the qualifying CT scan Biopsy of nodule prior to DCE-CT scan Contra-indication to potential radiotherapy or surgery Contra indication to scans (assessed by local procedures)


A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

eligible ages (years): 18.0-999.0,  All  PROSTATE CANCER Treatment naïve group Men with no prior diagnosis of prostate cancer undergoing prostate biopsy based on identified lesions on imaging Men with a raised PSA above 15ng/ml Men giving informed consent Treated men Men undergoing tissue biopsy for suspicion of prostate cancer recurrence following previous local or systemic therapy based on identified lesions in multi-parametric MRI, bone-scan, choline PET/CT, or PET/MRI  Unable to have MRI scan or CT scan, or in whom artefact would reduce scan quality Unable to have prostate biopsy Unable to undergo biopsy for metastatic evaluation On immunosuppression or predefined immunosuppressed state A coagulopathy predisposing to bleeding Unable to give informed consent


eligible ages (years): 18.0-999.0,  All  Solitary Pulmonary Nodule Bronchial Neoplasms age over 18 years Planed thoracoscopic surgery of a pulmonary nodule Informed consent  mental incapacity contraindications for this treatment pregnancy


eligible ages (years): 18.0-999.0,  All  Squamous Cell Carcinoma of the Anus Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus Age ≥18 years ECOG Performance status ≤2 Measurable disease according to Response Evaluation in Solid Tumours (RECIST) version 1.1 Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus HIV+ patients will be considered eligible with a CD4 count of ≥200 Adequate cardiac and respiratory function; absolute neutrophil count (ANC) ≥1.5x10^9/l; white blood cell (WBC) count ≥3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) ≥9g/dl; creatinine clearance >50ml/minute; serum bilirubin ≤1.5x upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5x ULN; alkaline phosphatase (ALP) ≤3x ULN Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy Life expectancy of at least 3 months  Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease Surgery or palliative radiotherapy within 28 days of randomisation Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome (naso-gastric or jejunostomy feeding tube is permitted) Acute hepatitis C and/or chronic active hepatitis B infection Serious active infection requiring i.v. antibiotics at enrolment


eligible ages (years): 18.0-999.0,  All  Acute Respiratory Distress Syndrome (ARDS) intubation and mechanical ventilation in the ICU Ramsay score 6 under sedation and analgesia ICU respirator implemented with pressure-volume curve device age equal to or greater than 18 years ARDS defined from the Berlin absence of pneumothorax on the CXR before the study Absence of pleural effusion greater than 500 ml estimated from ultrasonography no child-bearing woman written inform consent signed by the next of kin  Pneumothorax Pleural effusion greater than 500 ml estimated from ultrasonography Thoracic surgery in the last 3 months Contra-indication to CXR contra-indication to PEEP of 15 cm H2O contra-indication to PEEP of 15 or PEEP 15 mandated pressure-volume curve not feasible refusal to participate language barrier of the next of kin child-bearing woman


eligible ages (years): 18.0-999.0,  All  Lung Cancer Subjects of all races and ethnic origins over 18 years of age will be recruited Patients must have suspicious or known to be malignant solitary pulmonary nodule,5cm or less in size  Patients with a contraindication to MRI examinations will be excluded from this study Contraindications to MRI examinations Medically unstable Heart failure Unstable angina Child bearing Lactating Not a surgical candidate Any contraindication per MRI Screening Form (Appendix A attached). This is the same form used in clinical practice at UT Southwestern Titanium implants, pacemakers


eligible ages (years): 18.0-90.0,  All  Stroke Upper Extremity Paresis age between 18-90 years old hemisyndrome (central paralysis of the upper extremity, and all degrees of weakness: M0 M5 on the paresis scale) as a result of a first stroke sub-acute lesion not more than 6 weeks post ictus  insufficient state of consciousness severe aphasia severe cognitive deficits severe pathologies of the upper extremity of traumatic or rheumatic nature severe pain in the affected arm Patients with pacemakers and other active implants


eligible ages (years): 21.0-999.0,  All  Video-assisted Thoracoscopic Surgery (VATS) One-lung Ventilation signed informed consent elective left video-assisted thoracoscopy one lung ventilation  Anticipated difficult mask ventilation or intubation tracheal or high bronchial origin of the right upper lobe main bronchus severe COPD or asthma pleural disease previous left thoracic surgery chest radiotherapy chimiotherapy significant systemic co-morbidity active or chronic pulmonary infection fibrosis, other interstitial diseases


eligible ages (years): 18.0-65.0,  All  Asthma Bronchial Asthma Males or females age 18 or greater and 65 or less The diagnosis of asthma confirmed by at least one of the following as assessed at least once during the past 5 years before the study Reversibility to β2-agonists ≥12% predicted and ≥200ml after 400μg inhaled salbutamol or equivalent Bronchial hyper-responsiveness to methacholine or histamine Peak-flow variability of >20% over a period of 14 days Fall in FEV1 >12% and >200ml when tapering treatment (ICS, oral steroid, LABA and/or LTRA) Subject is taking regular maintenance medication (GINA step 4-5) for past 6 months that includes Inhaled corticosteroid at a dosage ≥500μg fluticasone equivalent per day AND Long acting ß2-agonist at a dosage of ≥100μg per day salmeterol dose aerosol or equivalent) Per protocol bronchial hyper-responsiveness to methacholine (PC20<4 mg/ml)  Asthma exacerbation during the prior 4 weeks Subject has 5 or more hospitalizations for exacerbations of asthma in the previous year or 1 or more ICU admission for mechanical or endotracheal intubation for asthma in the previous year Respiratory tract infection within past 4 weeks Subject has a known sensitivity to medications required to perform bronchoscopy Subject is using immunosuppressant therapy other than oral steroid therapy Subject is on anticoagulant medication including anti-platelet agents Subject has bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 125,000/mm2 or known coagulopathy (INR >1.5) Subject has other respiratory diseases including interstitial lung disease, emphysema, cystic fibrosis, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (total IgE of >1000 Units/mL with positive specific IgE to aspergillus and evidence of central bronchiectasis) Subject has segmental atelectasis, lobar consolidation, significant or unstable pulmonary infiltrate, or pneumothorax, confirmed on x-ray. Bronchiectasis on HR-CT-of the chest, both centrally or peripherally will be excluded Subject has clinically significant cardiovascular disease, including myocardial infarction, angina, cardiac dysrhythmia, conduction defect, cardiomyopathy, aortic aneurysm, or stroke at the discretion of the investigator


eligible ages (years): 18.0-999.0,  All  Metastatic Anaplastic/Undifferentiated Thyroid Cancer Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Histologically or cytologically confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer that demonstrates mutation in the ALK gene as assessed by sequencing of the tumor specimen for Arm A. Other ALK abnormalities as detected by the approved FISH test (Abbott Molecular Inc), using Vysis breakapart probes (defined as 15% or more positive tumor cells); or the Ventana IHC test will also be seen as evidence of ALK abnormality and meeting requirement Patients will not have any other curative therapeutic option, such as radiation or surgery WHO performance status 0-2 Age greater then or equal to 18 years Patients must have recovered from all toxicities related to prior anticancer therapies to ≤ Grade 2 (CTCAE v 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib. Exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment Adequate organ function: the following laboratory have been met Absolute neutrophil count (ANC) greater then or equal to 1.5 x 109/L Hemoglobin (Hgb) ≥ 8 g/dL Platelets greater then or equal to 75 x 109/L Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN), except for patients with Gilbert's syndrome who may be included if total bilirubin ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN  Patients eligible must not meet any of the following Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate) Patients with symptomatic CNS metastases who are neurologically unstable or have required increasing doses of steroids within the 1 week prior to study entry to manage CNS symptoms Prior therapy with ceritinib Presence or history of a malignant disease other than thyroid cancer that has been diagnosed and/or required therapy within the past year and is undergoing active anticancer treatment. Exceptions to this the following: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention) Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months), such as unstable angina within 6 months prior to screening myocardial infarction within 6 months prior to screening history of documented congestive heart failure (New York Heart Association functional classification III-IV)


eligible ages (years): 18.0-999.0,  All  Melanoma Brain Metastases Cohort 1 and 3 ≥18 years of age Written informed consent AJCC Stage IV (any T, any N, M1c) histologically confirmed melanoma or unknown primary melanoma. Patients must have at least 1 radiological definitive brain metastasis that is ≥ 5mm and ≤40mm measurable per version 1.1 guidelines In patients with prior BRAF inhibitor treatment, intracranial disease progression must be demonstrated (RECIST >20% or new measurable brain metastases) compared with nadir of intracranial response during BRAF inhibitor treatment, and confirmed with a second MRI brain scan after drug washout period (+/‐ 3 days) No prior localised treatment for brain metastases (eg. surgery or radiotherapy) Neurologically asymptomatic from brain metastases Eastern Cooperative Oncology Group (ECOG) Performance Status of 0‐2, and life expectancy > 30 days Able to undergo MRI with Gadolinium contrast agent Adequate haematological, hepatic and renal organ function  Any melanoma brain metastasis >40mm Ocular melanoma Prior treatment with an anti‐PD‐1 or anti‐PD‐L1 , anti‐PD‐L2, anti‐CD137, or anti‐CTLA‐4 antibody, or any other antibody or drug specifically targeting T‐cell co‐stimulation or checkpoint pathways Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll Current systemic treatment with corticosteroids, except prednisone at nonimmunosuppressive doses of ≤ 10 mg/day (or equivalent). Past treatment for non‐neurological symptoms allowed, if ceased 2 weeks prior to starting study treatment. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient on a stable dose. Non‐absorbed intraarticular steroid injections will be permitted Any investigational drug or other systemic drug therapy for melanoma within 28 days or 5 half‐lives from baseline Known to be HIV positive, or a positive test for hepatitis B and C  Another malignancy or concurrent malignancy unless disease‐free for 3 years Serious or unstable pre‐existing medical conditions or other conditions that could interfere with the patient's safety, consent, or compliance Pregnant or breastfeeding females


eligible ages (years): 18.0-75.0,  All  Melanoma Cutaneous melanoma with a tumour thickness of at least 1,00mm Positive sentinel node with micro metastases of max. 2mm in diameter  Mucosal or ocular melanoma Cutaneous melanoma located in the head/neck region Evidence of satellite, in transit or local metastases / recurrences Macro metastases of the SN or micro metastases of >2mm in diameter Additional immune-suppressive therapy Pregnant of lactating women


eligible ages (years): 0.0-999.0,  All  Rectal Neoplasms Patients with biopsy-proven confirmed rectal cancer MRI stage: T3/T4 and/or N1/N0 No contraindication to MRI and PET-CT  Contraindication to MRI and/or PET-CT Inability to consent Severe claustrophobia Distant metastases Synchronous tumour


eligible ages (years): 18.0-50.0,  All  Frontal Lobe Epilepsies (Patients) Age between 18 and 50 Diagnosis of frontal lobe epilepsy Written consent to participate Right-handed Hospital Anxiety and Depression Scale Score under 10 Obsessive Compulsive Inventory Score under 40 Sufficient language skills Social insurance (controls)  (Patients) Seizures types other than epileptic (psychogenic etc.) Mental retardation Epilepsies other than FLE Other known neurological diseases Hospital Anxiety and Depression Scale Score over 10 Obsessive Compulsive Inventory Score over 40 Pregnancy non-MRI suitable transplants (cardiac pacemaker etc.), claustrophobia, orthopedic diseases that prevent lying in the scanner During period of other studies


eligible ages (years): 40.0-999.0,  All  Lung Cancer COPD Subjects must meet all of the following Be enrolled in COPDGene® Phase 1 with or without enrollment in Phase 2 with newly diagnosed, (within the time of enrollment), non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) Documented GOLD stage 1-4 COPD or a history of smoking with no COPD Signed HIPAA Research Authorization and a Release of Protected Health Information form to collect and review medical records regarding lung cancer diagnosis, treatment, and outcome


eligible ages (years): 55.0-74.0,  All  Lung Carcinoma Solitary Pulmonary Nodule Cigarette Smoker Patients at high risk for lung cancer as defined by the United States Preventive Services Task Force (USPSTF) for lung cancer screening, with a newly discovered indeterminate pulmonary nodules (IPN) (7-30 mm diameter) on CT (newly seen on medical imaging, without prior examinations to demonstrate that the lesion has been stable for two or more years), untreated The patient is aged 55 to 74 years of age, AND Has a 30 or more pack-year history of smoking, AND Currently smokes, or, if the patient has quit smoking, has quit within the last 15 years, or An adult patient with a newly diagnosed, untreated primary lung cancer, with a minimum diameter of 7 mm The patient must be able to give informed consent, which will a layman's explanation of the estimated amount of additional radiation that the patient will receive from the investigational PET/CT scan using 18F-FSPG  Pregnant or lactating patients will be excluded, as will females of childbearing potential who refuse to undergo a serum or urinary beta-human chorionic gonadotropin (HCG) pregnancy test the day of either the 18F-FSPG or the 18F-FDG PET/CT scans Patients with a body weight of 400 pounds or more or a body habitus or disability that will not permit the imaging protocol to be performed The patient's inability to lie still for the entire imaging time (such as due to cough, severe arthritis), as assessed upon pre-enrollment screening, will not be enrolled A recognized active lung infection Previous systemic or radiation treatment for cancer of any type within 2 years Refusal to undergo a clinically indicated biopsy or a 24-month period of follow-up, if needed, to resolve the etiology of their IPN (benign versus cancer) Non-oncologic co-morbidities suggesting a life span of less than two years if not treated, as determined by the potential subjects' treating physician


eligible ages (years): 18.0-999.0,  All  Lung Cancer Pulmonary nodule on a recent CT non-visible on standard-size bronchoscopy  missing informed consent


eligible ages (years): 40.0-999.0,  All  Lung Diseases, Interstitial Lung Cancer equal to above 40 years old


eligible ages (years): 18.0-999.0,  All  Rectal Neoplasms Adenocarcinoma of the rectum classified clinically T2, T3a, T3b (penetration in the mesorectal fat between 1 to 5 mm) by TNM classification (Tumour Node Metastase), < 5 cm largest diameter, < half rectal circumference (by MRI staging), N0-N1 (any node < 8 mm diameter on MRI), M0 Operable patient Tumour accessible to endocavitary contact X-Ray Brachytherapy with a distance from the lower tumour border to the anal verge ≤ 10cm 18 years or above No comorbidity preventing treatment Adequate birth control Patient having read the information note and having signed the informed consent Health care insurance available Follow-up possible  Inoperable patient T1, T3cd, T4, T≥ 5cm, T≥ ½ circumference Patient N2 at diagnosis or N1 with any node > 8 mm diameter Patient presenting metastasis at diagnosis Previous pelvic irradiation Tumour with extramural vascular invasion Simultaneous progressive cancer Tumour invading external anal sphincter and within 1 mm, and the levator muscle Patient unable to receive CXB or CRT Tumour with poor differentiation (G3)


eligible ages (years): 55.0-75.0,  All  Lung Cancer relatives of the lung cancer patients age older than 55 years old or age older than the age of onset of lung cancer proband if the family members were less than 55 years old compulsory signing the consent agreement after understanding the purpose of study and the exposure of radiation  proved lung cancer either with or without treatment presence of hemoptysis or history of remarkable lung fibrosis any other cancer history or chest CT examination within one year


eligible ages (years): 18.0-999.0,  All  Prostatic Neoplasms Able to provide informed consent ECOG performance status 0-1 Histologic confirmation of prostate adenocarcinoma Stage IV disease, with up to 5 metastatic tumours outside of the prostate and pelvic lymph nodes ≤ 3 tumours within any given organ system (e.g. up to 3 brain metastases, or 3 liver metastases) All sites of disease are amenable to stereotactic radiotherapy  Castrate resistant prostate cancer Evidence of spinal cord compression Previous radiotherapy for current cancer (with the exception of upfront management of the primary prostate tumour, brain metastasis(es) prior to androgen deprivation therapy) Inability to safely treat all sites of visible disease Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer


eligible ages (years): 21.0-999.0,  All  Solitary Pulmonary Nodule Coin Lesion, Pulmonary Lung Neoplasms Carcinoma, Non-small-cell Lung The target population includes adults with small lung nodules that may represent a new diagnosis of lung cancer, who typically would be managed by CT surveillance in usual clinical practice. Thus, we will enroll all adult patients aged ≥21 years at least one nodule measuring ≤15 mm in widest axial diameter on chest CT  Pregnant Women Children Known diagnosis of cancer (except non-melanoma skin cancer) within 5 years Multiple (>10) nodules on chest CT scan


A 72-year-old man complains of increasing calf pain when walking uphill. The symptoms have gradually increased over the past 3 months. The patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago. Over the past month, his blood pressure has worsened despite previous control with diltiazem, hydrochlorothiazide, and propranolol. His is currently taking isosorbide dinitrate, hydrochlorothiazide, and aspirin. On physical examination, his blood pressure is 151/91 mm Hg, and his pulse is 67/min. There is a right carotid bruit. His lower extremities are slightly cool to the touch and have diminished pulses at the dorsalis pedis.

eligible ages (years): 45.0-74.0,  All  Cardiovascular Diseases Heart Diseases Atherosclerosis Asthma Carotid Artery Diseases Coronary Disease Hypercholesterolemia Hypertension Diabetes Mellitus Obesity


eligible ages (years): 0.0-999.0,  All  Atherosclerosis Coronary Disease Arterial Occlusive Diseases Peripheral Vascular Diseases Cardiovascular Diseases


eligible ages (years): 0.0-999.0,  All  Cardiovascular Diseases Peripheral Vascular Diseases Atherosclerosis Cerebrovascular Disorders Myocardial Infarction Heart Diseases Hyperhomocysteinemia


eligible ages (years): 18.0-999.0,  All  Diabetes Mellitus, Type 2 Intermittent Claudication Group I (n=25 PAD patients). This sample will represent the population of veterans with PAD with mild mobility impairment secondary to intermittent claudication in the gastrocsoleus muscles for PAD Subjects diagnosis of PAD (acute or chronic occlusive arterial disease), with or without diabetes mellitus positive Edinburgh Claudication Questionnaire Fontaine stage IIa only (mild claudication, walking distance > 200 feet (one-half block) ambulatory, without assistive devices calf muscle claudication within 10 minutes of treadmill walking and calf muscle exercise Group II (n=25 normal control/reference subjects). This reference sample will represent the population of adults without PAD and related problems. They will undergo the PET-exercise testing for perfusion and glucose metabolism measurements, but will not perform the exercise training intervention for Controls healthy adults, matched by age and sex to PAD subjects  for PAD and Control Subjects PAD secondary to Buerger's disease, autoimmune arteritis, fibromuscular dysplasia, chronic and repetitive occupational trauma, venous stasis, hypercoagulability disorder, or arterial embolic disease inability to perform ankle dorsi and plantar flexion exercise cigarette smoking within last 6 months severe claudication, leg rest pain, skin ulceration, necrosis or gangrene (Fontaine stage >= IIa) poorly controlled diabetes mellitus (bA1c >= 9%) poorly controlled hypertension (resting BP > 140/90 mmHg) Raynaud's syndrome changes in prescribed cardiovascular medications within the past 6 months exertional angina, dyspnea, fatigue, or dizziness


eligible ages (years): 50.0-75.0,  All  Hypertension Postmenopausal women Mild to moderate hypertension Statin therapy or LDL≤ 4.1 mmol/L  Severe hypertension LDL > 4.1 mmol/L if not taking anti-hyperlipidemic medication Certain hormonal therapy History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease Diabetes Raynaud's disease or any other significant peripheral vascular disease Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/


eligible ages (years): 18.0-90.0,  All  Peripheral Vascular Diseases Receive stable peritoneal dialysis patients for more than 3 months  Active infection, malignancy and recent hospitalization


eligible ages (years): 18.0-999.0,  All  Hypertension 18 years of age Patients with stage II systolic hypertension If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study  Hypertensive encephalopathy, stroke or transient ischemic attack (TIA) within the past 6 months History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months Severe hypertension (DBP greater than or equal to 110 mm Hg or SBP > 200 mm Hg) History of secondary hypertension including renal disease, phaeochromocytoma, or Cushing's disease Type I diabetes mellitus. 6. Evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease Presence of heart block greater than first degree sinoatrial block, Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial fibrillation, or Atrial Flutter Laboratory test values considered clinically significant by the investigator Evidence of liver disease as indicated by SGOT or SGPT and/or total bilirubin > 3 times the upper limit of normal Pregnant or lactating females Patients with malignancy during the past 5 years excluding squamous cell or basal cell carcinoma of the skin


eligible ages (years): 18.0-70.0,  All  Tachycardia Chronic Orthostatic Intolerance Chronic symptoms (> 6 months) with standing upright  Obvious cause of hypovolemia or drugs that could worsen tachycardia Chronic severe medical conditions such as cancer or ischemic heart disease


eligible ages (years): 18.0-80.0,  All  Venous Insufficiency Diabetes Diabetic ulcer, OR Venous insufficiency ulcer Age range: 18-80 years Wound max. diameter range: 1.5 centimeters Wound San Antonio assessment system: grade 1 and 2, stage A and B Palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries Ankle-Brachial Index > 0.7 by Doppler Wound present for at least 6 weeks Wound location: foot or calf, at a location where the device can be attached properly Lack of purulent discharge from the wound  Hypoalbuminemia: Albumin < 2gr/dl Right-side congestive heart failure with edema of legs: +2 or higher Renal insufficiency: Cr > 2 mg/dl Abnormal liver function: ALT or AST>300 Skin disorders adjacent to the wound, unrelated to the pathology of the wound Non-cooperative patient


eligible ages (years): 21.0-999.0,  All  Peripheral Artery Disease Severe Intermittent Claudication Males or females equal to or greater than 21 years old Patients with infra-inguinal atherosclerosis with a stenosis or occlusion of a major vessel in the affected limb(s) of one or more of the following arteries: superficial femoral, popliteal, or one or more infrapopliteal arteries, which is/are non-reconstructable Patients with symptoms of Severe Intermittent Claudication in at least 1 lower limb persisting for at least 6 months (Rutherford Class 3) Patients who have a diagnosis of Peripheral Arterial Disease (PAD) in at least 1 lower limb secondary to atherosclerosis, for at least 6 months  Patients who have had successful aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 3 month preceding screening Patients with iliac disease amenable to revascularization Patients judged to be a suitable candidate for surgical or percutaneous revascularization in the limb in which treatment is proposed Patients with Critical Limb Ischemia (CLI), Rutherford Symptom Score of 4,5, or 6 Patients in who arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder


eligible ages (years): 16.0-999.0,  All  Diabetes Mellitus Hypertension Dyslipidemia Obesity Cardiovascular Disease Coronary Artery Disease Age 16 years or more Informed consent Living in selected community (Health Promotion area of Rajavithi Hospital)


eligible ages (years): 18.0-999.0,  All  Peripheral Vascular Disease Written informed consent Age > 18 years If female patient with child bearing potential, patient may not be pregnant at the study entry and must utilize reliable birth control for the duration of her participation into the study Patient is willing and able to comply with the specified follow-up evaluation Critical Limb Ischaemia, this is Fontaine stage III (ischaemic rest pain) and IV (ischaemic ulcers or gangrene) or Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss) or 6 (major tissue loss) Stenotic (>50% luminal loss) or occluded infrapopliteal artery, including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the peroneal artery, with a lesion length ≤ 60 mm Artery to be treated with a diameter more tham or equal to 2mm and less than or equal to 4mm Patent common iliac, external iliac, superficial femoral and popliteal artery on the ipsilateral side prior to randomisation, possibly after treatment during the same session At least one patent crural (anterior tibial, posterior tibial or peroneal) artery with expected unobstructed runoff to ankle level after treatment  Acute limb ischaemia Subacute limb ischaemia which requires thrombolysis as first treatment modality Active bleeding or bleeding diathesis Recent (less than 3 months) hemorrhagic stroke or other any other CNS abnormality with increased risk of haemorrhage, such as intracranial neoplasm, arteriovenous malformation, intracranial aneurysm or aneurysm repair Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks before treatment Aneurysm in common femoral, superficial femoral or popliteal artery on the ipsilateral side Revascularization involving the same limb within 30 days prior to the index procedure or planned revascularization of the same limb within 30 days of the index procedure Previous implanted stent at the index site Life expectancy of less than 6 months or other factors making clinical follow-up difficult Known allergy to acetylsalicylic acid (aspirin), clopidogrel, heparin or paclitaxel


eligible ages (years): 18.0-999.0,  All  Coronary Artery Disease Peripheral Vascular Disease Patient ≥ 18 years old Coronary or peripheral vascular intervention 6 French arterial sheath used Overnight hospitalization following procedure  Hematoma or persistent bleeding around the vascular sheath Previous AV fistula or pseudoaneurysm in the ipsilateral femoral artery History of bleeding diathesis or coagulopathy Hemoglobin level < 9 g/dl Inability to ambulate at baseline Known allergy to any of the materials used in the SafeSeal Female patients known to be pregnant or lactating Evidence of ongoing systemic or cutaneous infection Uncontrolled blood pressure following PCI (systolic blood pressure > 180 or diastolic blood pressure >110) Current enrolment in another ongoing investigational drug/device trial


eligible ages (years): 18.0-85.0,  All  Lower Extremity Chronic Venous Ulcers Patient must have a venous leg ulcer Participants, either men or women are between 18 and 85 years of age Clinical presentation of venous insufficiency demonstrated by Doppler Ankle-Brachial Index > 0.7 by Doppler Good palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries Wound present for at least 6 weeks prior to enrolment Wound length is in the range of: 1.5 centimeters The necrotic tissue area is at least 20% of wound area. (by clinical evaluation, i.e., inspection) Wound San Antonio classification: Grade 1 or 2, Stage A or B  Documented sensitivity to Papain, by medical history records Patients in need of surgical debridement Patients with general skin disorders (Psoriasis, Peniculitis ect) that might deteriorate as a result of local trauma Patients with skin disorders unrelated to the ulcer that are presented adjacent to the wound Pain sensation is completely absent (wound area is anesthetic) Patients with renal failure. (Cr > 2 mg/dl) Patients with impaired hepatic function (ALT, AST or GGT 2-fold higher than normal upper limit value) Patients having Hypoalbuminemia: (Albumin < 2gr/dl ) Patients with general Immunological disorders that might deteriorate as a result of local trauma Right-side congestive heart failure (CHF) with edema of legs: (NYHA class 2 or higher see 5)


eligible ages (years): 50.0-80.0,  All  Cardiovascular Disease Hypertension Hyperlipidemia Heart Disease All men over 50 to 80 and all women 55 to 80 who are resident in Kalaleh, Golestan, for at least one year  Existing cardiovascular disease (stroke, transient ischaemic attack, myocardial infarction or angina) Already taking antihypertensive drugs, aspirin or statins Already have clinical indications for treatment with antihypertensive drugs, aspirin or statins Blood pressure >160/100 mm Hg Total Cholesterol > 240 mg/dL (or LDL >190 mg/dL) Probable diabetes: HbA1c >6.0 Contraindication to a component of the Polypill Contraindications to aspirin Previous history of allergy to aspirin History of peptic ulcer bleeding in whole life or endoscopic evidence of peptic ulcer within the past 3 months


eligible ages (years): 19.0-999.0,  All  Critical Limb Ischemia Severe Leg Ischemia Peripheral Artery Disease Peripheral Vascular Disease Males or females older than 18 years of age Limb ischemia with ABI of < 0.7 in the index lower extremity in two consecutive examinations done at least 1 week apart Limb ischemia with resting ischemic pain and/or claudication at 100 meters and/or non-healing ulcers Claudication Patients not considered candidates for surgical or percutaneous revascularization, due to poor target vessels, inability to cross total occlusions, or a morbidity which precludes general anesthesia  Inability to provide informed consent Previous angiogenic therapy Known sensitivity to gentamycin and/or amphotericin B Use or expected use of antineoplastic drugs Any illness, which might affect the patient's survival after enrollment in the protocol Any illness or significant laboratory abnormality, which in the investigator's judgment will interfere with the patient's ability to comply with the protocol, compromise the patient's safety, or interfere with the interpretation of the study results No evidence of acute infection WBC > 15000 WBC < 4000 Serum Creatinine > 3.0 mg/dL in patients who are not in hemodialysis


eligible ages (years): 40.0-999.0,  All  Intermittent Claudication Aged 40 or older, male or female mo. history of walking limitation or symptoms of intermittent claudication (IC) in at least 1 lower limb, severity of which has not changed in the past 3 mo. and diagnosed by principal investigator as clinically stable Fontaine Stage II peripheral artery disease (PAD) Diagnosis of PAD secondary to atherosclerosis If ankle-brachial index (ABI) is > 1.3 or cannot be measured in either leg, vascular etiology documented by toe-brachial index (TBI) ≤ 0.7 in at least 1 leg Claudication severity, meds. for the treatment of coronary artery disease (CAD), PAD and IC, and exercise habits should be clinically stable for 3 mo. prior to Screening (SCRN) and during study. Pt. is not likely to change smoking and/or exercise habits during study On an exercise treadmill test (ETT), peak walking time (PWT) of at least 1 min., but no more than 12 min. at Baseline Willing and able to discontinue Pletal or Trental for 21 days before SCRN and during study Antihypertensive therapy, cholesterol-lowering therapy, chronic oral nitrates, and diabetic therapy have been stable for 30 days prior to SCRN Willing and able to provide written, signed, informed consent after the nature of the study has been explained and prior to any research-related procedures Willing and able to comply with all study-related procedures  Pregnant or lactating Current or history of critical limb ischemia (CLI) Pts. in whom artery insufficiency in the lower extremity is the result of acute limb ischemia (ALI) or an immunological or inflammatory non-atherosclerotic disorder Pts. in whom walking impairment due to pain is the result of other non-atherosclerotic co-morbid conditions A surgical intervention to alleviate symptoms of IC or PAD-specific endovascular intervention or cardiovascular surgery within 3 mo. of SCRN Walking limited by reasons other than claudication Conditions other than IC of significant severity that could confound PWT on the ETT Concurrent severe congestive heart failure (CHF) Life-threatening ventricular arrhythmias, unstable angina, and/or myocardial infarction (MI) within 3 mo. before enrollment (ENRL) Coronary artery bypass grafting or percutaneous coronary intervention within 4 mo. before ENRL


eligible ages (years): 18.0-999.0,  All  Hypertension Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed Men or women 18 years and older of African American background; self identified Patients with stage 2 hypertension. Patients must have a MSSBP ≥ 160 mmHg and < 200 mmHg at Visit 5 (randomization)  Office blood pressure measured by cuff (MSSBP ≥ 200 mmHg and/or MSDBP ≥ 110 mmHg) at any visit Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives whichever is longer History of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (CCBs or thiazide diuretics) as the study drugs Long QT syndrome or QTc > 450 msec for males and > 470 msec for females at screening History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method Adequate barrier methods of contraception diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives any marketed contraceptive agent that includes an estrogen and/or a progestational agent. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment History or evidence of a secondary form of hypertension


eligible ages (years): 39.0-70.0,  All  Lower Extremity Ischemia an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification) a painless walking distance of 10-50 m pulse absence on аа. dorsalis pedis, tibialis posterior, poplitea absence of a ischemia in a rest and necrotic changes mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries) according to an angiography that testifies to impossibility of reconstructive operation performance patients after a lumbar sympathectomy and a tibial bone osteoperforations executed previously heavy smokers  insulin depended diabetes myocardial infarction or a stroke within last year an idiopathic hypertensia III stage anaemia and other diseases of blood decompensation of the chronic diseases which are contraindications to any surgical operation HIV infection a virus hepatitis oncologic diseases chemotherapy in the anamnesis


eligible ages (years): 18.0-90.0,  All  Peripheral Arterial Disease Male or female subject 18 to 90 years, of any race Patients with proven Peripheral Arterial Disease (PAD) in Doppler Ultrasound and Ankle-Brachial Pressure Index (ABPI ≤ 0.9 in one leg) Subject with stable (>3 month) PAD Fontaine Stage II Aortoiliac vessels with no significant hemodynamic disturbances , as confirmed by recent (<30 days) clinical examination Subject has intermittent claudication and claudication pain of the calf Subject has stable intermittent claudication (>3 month and not more than one year) with initial claudication distance not more than 250 meters, as determined by treadmill test (3.2 km/h, 10% grade) Subject willing to participate as evidenced by signing the written informed consent Treatment with Aspirin or Clopidogrel for at least 7 days Willingness to undergo standardized walking exercise  Ankle-Brachial Pressure Index (ABI) above 0.8 in both legs. In Diabetic patients with no compressible arteries ABI above 40 mm/Hg of the higher pressure measured in both arms Inability to walk Chronic respiratory insufficiency (severe obstructive or restrictive) Coronary artery disease with angina Stroke, myocardial infarction or other acute vascular events in the last 3 months Mild-Severe congestive heart failure Degenerative or inflammatory hip, knee, ankle or foot joint lesions interfering with walking Spinal stenosis or disc lesions with lower limb motor sensory defects Leg trauma, limb or skin infection or edema Recent (6 months) abdominal, cardiothoracic, vascular or orthopedic (lower limb) surgery


eligible ages (years): 50.0-85.0,  All  Chronic Limb Ischemia Non-Healing Ulcers Patients with established diagnosis of lower limb ischemic based on their symptoms of claudication, rest pain, non-healing ulcers or gangrene and other vascular laboratory tests that are currently used to make this diagnosis and have been scheduled for endovascular revascularization Age group between 50-85 Gender Male or Female Race all race and ethnicities  Patients with known cardiac disease new MI (within 3 months) Patients with hypertension with the systolic BP >200 or diastolic BP>110 on the day of testing Patients on supplemental O2 for chronic obstructive lung disease Bed-ridden subjects either due to chronic disability or neurological problems


eligible ages (years): 40.0-999.0,  All  Peripheral Arterial Disease Subjects with peripheral arterial disease for more than 6 months Male or female with claudication secondary to lower extremity atherosclerotic arterial disease. (with limited IC but not incapacitated for walking on the level) confirmed with ankle/brachial pressures< or = to 0.9 in one or both legs) or who have had a previous intervention for peripheral arterial disease Over 40 years old Able to comply with protocol requirements Able to provide informed consent Subjects taking anti-platelet therapy medication must be on a stable dose for 3 months prior to as well as during the study Subjects taking lipid lowering medication must be on a stable dose for 3 months prior to as well as during the study  Patients with ischemic rest pain in limbs, ulceration, or gangrene At baseline, any condition that prevents walking on a treadmill History of major bleeding Patients with bowel disease (including Crohn's disease, celiac disease, peptic ulcer disease, irritable bowel syndrome and diverticulosis) Patients with an estimated life expectancy less than 2 years and with high baseline cardiac risk (post ischemic or diabetic cardiomyopathy with EF<40%, Canadian Cardiovascular Society Class 3 or 4 angina or need for coronary revascularization procedures) Moderate to severe renal failure Subjects that are on supplements other that those prescribed by their clinician for the entire duration of the study Fish limitations (no more than 2 fish meals per week) Gluten allergy Subjects with allergies to any ingredient in the study product or placebo


eligible ages (years): 18.0-999.0,  All  Peripheral Arterial Disease Claudication Critical Limb Ischemia Has a Rutherford Clinical Category Score of 1 Has evidence of ≥ 50% stenosis or occlusion in the superficial femoral, popliteal, anterior tibial, posterior tibial and/or peroneal arteries, confirmed by angiography Has identifiable distal target vessel which upon completion of the intervention, is anticipated to provide re-constitution of blood flow to the foot Exchangeable guidewire must cross lesion(s), with ability of catheter to cross lesion Each discrete target lesion's length is ≤ 20 cm Reference vessel diameter is ≥ 1.5 mm and ≤ 7 mm  Has surgical or endovascular procedure of the target vessel within 14 days prior to the index procedure Has any planned surgical intervention or endovascular procedure within 30 days after the index procedure Has had a previous peripheral bypass affecting the target limb Has end-stage renal disease defined as undergoing hemodialysis for kidney failure Has presence of severe calcification in target lesion(s) Has in-stent restenosis of the target lesion Has an aneurysmal target vessel Has significant stenosis or occlusion of inflow tract that has not been revascularized prior to treatment of the target vessel Has perforation, dissection or other injury of the access or target vessel requiring additional stenting or surgical intervention prior to enrollment Has disease that precludes safe advancement of the SilverHawk/TurboHawk device to the target lesion(s)


eligible ages (years): 0.0-0.019,  All  Cerebral Oxygenation Cerebral Blood Flow Prematurity Preterm infant (Gestational Age <37+0) Peripheral arterial catheter (ulnary or radial artery)  Complex organ malformation


eligible ages (years): 30.0-999.0,  All  Peripheral Arterial Disease Peripheral arterial disease post surgery > 1 month No discharge of surgical incision Intermittent claudication post invasive treatment  Necrosis Above/below knee amputee Other conditions might affect peripheral vascular elasticity


eligible ages (years): 18.0-999.0,  All  Essential Hypertension Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg on Day, or has not received antihypertensive treatment within 14 days prior to Screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg at the Screening Visit and on Day 1 Females of childbearing potential who are sexually active agree to routinely use adequate contraception, and can neither be pregnant nor lactating from before study participation to Screening to 30 days after the last study drug dose Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant Is willing to discontinue current antihypertensive medications up to 3 weeks before enrollment  Has a mean clinic diastolic blood pressure (sitting, trough) greater than 119 mm Hg on Day 1 Has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome) Has a recent history (within the last 6 months) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack Has clinically significant cardiac conduction defects (ie, third-degree atrioventricular block, sick sinus syndrome) Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease Has severe renal dysfunction or disease Has known or suspected unilateral or bilateral renal artery stenosis Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug Has poorly-controlled type 1 or 2 diabetes mellitus at Screening Has hypokalemia or hyperkalemia at Screening


eligible ages (years): 18.0-75.0,  All  Painful Diabetic Neuropathy Age ≥ 18 years to 75 years Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of ≤ 10.0%) Diagnosis of painful diabetic peripheral neuropathy in both lower extremities The physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is ≥ 3 at Screening Visual analog scale (VAS) score of ≥ 4 cm at Screening (0 cm = no pain cm worst imaginable pain) Stable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes Lower extremity pain for at least 6 months If female of childbearing potential, negative pregnancy test at screening and using acceptable method of birth control during the study  Peripheral neuropathy caused by condition other than diabetes Other pain more severe than neuropathic pain Progressive or degenerative neurological disorder Myopathy Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease) Active infection Chronic inflammatory disease (e.g. Crohn's, Rheumatoid Arthritis) Positive HIV or HTLV at Screening Positive Hepatitis B or C as determined by Hepatitis B core antibody (HBcAB), antibody to Hepatitis B antigen (IgG and IgM; HbsAB), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV), at Screening or known immunosuppression or on chronic treatment with immunosuppressive drugs, chemotherapy or radiation therapy Stroke or myocardial infarction within last 6 months


eligible ages (years): 18.0-72.0,  All  Critical Limb Ischemia Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV) Participant must match either a or b Ankle brachial index (ABI) ≤ 0.7 Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure < 30 mmHg A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi segment disease, or extensive infra-popliteal disease not amenable to a vascular graft Age > 18 years old The non-index leg may be treated only in the event and it full fills the same and  used in this protocol for the treatment leg Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to < 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy) Popliteal vascular entrapment syndrome Lower extremity infection or infected ulcer Hypercoagulable state HIV positive HBsAg positive Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy Unstable angina Thrombocytopenia < 50,000/ul


eligible ages (years): 18.0-999.0,  All  Peripheral Arterial Disease patients at the time of diagnosis of Fontaine grade II peripheral arterial disease (PAD), confirmed by hemodynamic evaluation (Doppler ultrasound) over 18 years old  patients had previously undergone revascularization patients were receiving treatment with statins patients with contraindications to statin use patients with coexistence of chronic inflammatory diseases or steroidal medication


eligible ages (years): 18.0-999.0,  All  Peripheral Vascular Diseases Documented acute coronary syndrome (Unstable angina, non-Q-wave myocardial infarction, Q-wave myocardial infarction) or/and documented ischemic stroke/transient ischemic attack (IS/TIA)  Previously known symptomatic or asymptomatic PAD confirmed by one of the following diagnostic methods or interventions (documented in the patient's medical record) Non-invasive or invasive vascular diagnostic tools (e.g.: ABI, Toe-brachial index, Duplex ultrasound, Magnetic resonance angiography, Computer tomographic angiography, Contrast angiography) Previous related intervention (such as angioplasty, stenting, atherectomy, peripheral arterial bypass graft, other vascular intervention including amputation) Patients whose ABI cannot be measured accurately Patients already in a clinical trial or a product registry Hospitalized patients


eligible ages (years): 20.0-30.0,  All  Ischemic Preconditioning healthy volunteers aging 20-30 years old no cardiac，hepatic or renal，peripheral vascular diseases be willing to enter our study and sign an written informed consent  younger than 20 years old or older than 30 years old having cardiac，hepatic or renal，peripheral vascular diseases refuse to enter our study or sign an written informed consent


eligible ages (years): 40.0-999.0,  All  Peripheral Arterial Disease Criteria:Healthy age-matched participants (acute phase of the study) Healthy volunteers, male or female, > 40 years of age Body Mass Index 18-30 Glycated hemoglobin <6.5% Fasting serum total cholesterol <4 mmol/L and triglycerides <2.5 mmol/L Blood pressure <140/90 mm Hg Ankle-brachial index of >0.9 Willing to comply with the protocol requirements Willing to provide informed consent Participants having completed another food-related study are eligible to participate if it has been more than 3 months since their participation   healthy age-matched participants (acute phase of the study) Currently smoking, or smoking within the last 6 months (Note: cigar smoking on an occasional basis will be permitted) Presence of a clinically diagnosed disease affecting the heart, liver, kidneys, lungs,gastrointestinal, endocrine or blood/immune systems that requires medical treatment Taking any prescribed medication within the last 3 months with the exception of anti-depressants, birth control and hormone (estrogen) replacement therapy Pregnancy Amputation of upper or lower extremity on both sides Has undergone a surgical procedure requiring local or general anesthetic within the last 3 months History of gastrointestinal reactions or allergies to dietary oils and other ingredients in banana bread such as wheat and eggs Daily consumption of omega-3 supplements  Peripheral arterial disease participants (acute and chronic phases of the study)


eligible ages (years): 0.0-999.0,  All  Kidney Diseases Kidney Failure, Chronic Kidney Failure Renal Insufficiency Renal Insufficiency, Chronic Urologic Diseases Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation Living donors Compatible ABO blood type PRA < 20%  Re-transplant patients Those with peripheral vascular disease affecting the lower limbs


eligible ages (years): 18.0-999.0,  All  Cardiovascular Diseases Cardiovascular Risk Factor African American adults > 18 years old


eligible ages (years): 18.0-999.0,  All  Hypertension Essential hypertensive patient no less than 18 yeas old Patient who gave informed consent form  Patient was diagnosed as secondary hypertension Patient who have white-coat hypertension


eligible ages (years): 18.0-75.0,  All  Hyperlipidemia Coronary Artery Disease Written informed consent Men or women, aged 18 -75 Diagnosed with coronary heart disease (CHD) stable angina for more than 1 month and meet the following any one History of myocardial infarction CHD confirmed by coronary angiography Excercise ECG positive for CHD or perfusion defect One or more main branch of coronary artery stenosis ≥ 50% confirmed by CT scanning Hyperlipidemia (lipid-lowering treatment naïve: LDL-C ≥130mg/dl, or having received lipid-lowering treatment: LDL-C ≥100mg/dl) The 64 slice CT shows at least one significant coronary artery stenosis ≥20% with the narrowest ≤60% and meeting the following Diameter of coronary artery lesion ≥2mm, length ≥5mm; distance between multiple lesions ＞1cm  Acute myocardial infarction within 6 months PCI or CABG therapy within 6 months Anticipated PCI or CABG therapy in the following 3 months Tropnin I/Tropnin T higher than ULN Cardiac failure NYHA III or above Coronary artery left main stenosis >50% Emergency coronary angiography(CAG) is needed Serious arrhythmia or tachycardia Secondary hyperlipidemia Familial hypercholestrolemia


eligible ages (years): 18.0-85.0,  All  Sepsis Severe Sepsis All adult patients (>18 years) admitted to the intensive care with 1) hemodynamic instability due to severe sepsis, and 2) a mean arterial pressure < 65 mmHg and 3) an arterial lactate concentration > 3.0 mmol/L will be considered for participation  moribund severe coagulation disorder (contraindication for central venous catheter placement) severe peripheral vascular disease (interfering with peripheral perfusion measurement)


eligible ages (years): 60.0-85.0,  All  Peripheral Vascular Diseases male or female 85 years femoro-popliteal stenosis TASC B or C category HBA1c <9%, if diabetic creatinine <130µg/ml blood pressure <160/95mmHg thrombocyte aggregation inhibitors or coumarine derivatives  <60 or >85 years stenosis not in femoro-popliteal axis TASC A or D category HBA1c >9%, if diabetic creatinine >130µg/ml blood pressure >160/95mmHg major trauma malignancy anti-phospholipid syndrome relevant hepatic disease


eligible ages (years): 18.0-999.0,  All  Drug Safety The subject is over 18 years old Subjects are referred to undergo a peripheral arteriography as part of their routine clinical care  The subject has known allergies to iodine or any prior history of adverse reaction to iodinated CM The subject received another administration of CM within 24 hours prior to baseline or is scheduled to receive one within the 24 hour follow-up period The subject is pregnant or lactating The subject is taking metformin (e.g., Glucophage®) but is not willing or unable to discontinue at the time of the study procedure The subject manifests thyrotoxicosis or is on dialysis


eligible ages (years): 18.0-75.0,  All  Painful Diabetic Neuropathies Age ≥ 18 years to ≤ 75 years Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral medication and/or insulin Diagnosis of painful diabetic peripheral neuropathy in both lower extremities Lower extremity pain for at least 6 months Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain mm very severe pain) Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference between legs at Initial Screening The average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2 The physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is ≥ 3 at Screening Stable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes  Peripheral neuropathy caused by condition other than diabetes Other pain more severe than neuropathic pain Progressive or degenerative neurological disorder Myopathy Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease) Active infection Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) Positive HIV or HTLV at Screening Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAB), antibody to Hepatitis B antigen (IgG and IgM; HbsAb), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening Subjects with known immunosuppression or currently receiving immunosuppressive drugs, chemotherapy or radiation therapy


eligible ages (years): 18.0-999.0,  All  Peripheral Artery Disease Hypertension Men and non-pregnant, non-lactating women 45 years of age or older Able to give informed consent and complete scheduled visits Mild-moderate bilateral lower extremity peripheral arterial disease as defined by an ankle-brachial index (ABI measurement of 0.6-0.9. If a subject has baseline claudication symptoms, the symptoms must be stable for the 3 months preceding enrollment History of hypertension. Blood pressure at the screening visit must be ≤160/100 mmHg and ≥100/60 mmHg for all subjects. If a subject is currently prescribed beta-blocker therapy, BP at the screening visit must be ≤140/90 mmHg. In addition, heart rate must be ≥55 beats per minute if currently prescribed a beta-blocker and ≤60 beats per minute if not currently prescribed a beta-blocker At least moderate risk for CAD  Participation in another clinical trial Ongoing ischemic (resting) limb pain, or lower extremity ulceration due to arterial insufficiency, or an ABI indicating <0.6 indicating disease potentially requiring revascularization History of limb or digit amputation due to arterial insufficiency Revascularization of peripheral vessels within the preceding 6 months Uncontrolled hypertension as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg Contraindication or allergy to beta blocker therapy History of myocardial infarction , coronary revascularization, or a cerebrovascular event within the preceding 6 months Class III or IV angina Current or past history of New York Heart Association (NYHA) class III or IV heart failure Inability to walk on a treadmill for any reason


eligible ages (years): 18.0-999.0,  All  Lower Limb Ischaemia Aneurysm need for lower limb vascular by-pass surgery  allergic to cefuroxime patients refusal to participate


eligible ages (years): 18.0-999.0,  All  Blood Lactate Analysis Adult patients 18 years or older Admitted to the Intensive Care Unit (ICU) Determined by their treating clinicians to require both a central venous line and arterial line


eligible ages (years): 18.0-999.0,  All  Coronary Artery Disease Coronary Sinus Circulation, Collateral Ischemia Collateral Flow Index Age > 17 years Stable angina pectoris, patient electively referred for coronary angiography Written informed consent to participate in the study  Acute coronary syndrome; unstable cardio-pulmonary conditions Congestive heart failure NYHA III-IV Previous coronary bypass surgery Q-wave myocardial infarction in the area undergoing CFI measurement Anatomical variants not allowing coronary sinus occlusion Severe valvular heart disease Severe hepatic or renal failure (creatinine clearance < 15ml/min) Pregnancy


eligible ages (years): 18.0-999.0,  All  Abdominal Aortic Aneurysm Carotid Atherosclerosis Critical Lower Limb Ischaemia Age greater than 18 years patient willing to give full informed consent for participation Patients undergoing elective carotid endarterectomy or Patients undergoing open abdominal aortic aneurysm repair or Patients undergoing endovascular abdominal aneurysm repair or Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)  Patients less than 18 years of age Patients who are unable or unwilling to give full informed consent Pregnancy Significant upper limb peripheral arterial disease Patients on glibenclamide or nicorandil (these medications may interfere with remote ischaemic preconditioning) Patients with an estimated pre-operative glomerular filtration rate < 30mls/min/1.73m2 Patients with a history of myocarditis, pericarditis or amyloidosis Patients undergoing Fenestrated or branched EVAR


eligible ages (years): 18.0-999.0,  All  Bypass Complications Disorder of Blood Gas age > 18 years old undergoing totally thoracoscopic cardiac surgery with cardiopulmonary bypass  without informed consent pregnancy


eligible ages (years): 17.0-999.0,  All  Contrast Induced Nephropathy Remote Ischaemic Preconditioning Hospital inpatients undergoing contrast enhanced abdomino-pelvic CT scanning  Those with an allergy/hypersensitivity to the contrast solution Those with a Cr of above 150μmol/dL on admission, as is a contraindication to IV contrast Patients who are not getting IV contrast Any patients with a history of renal transplantation Any patients with a history of previous acute kidney injury necessitating management by a nephrologist Patients taking either a sulphonlurea or nicorandil


eligible ages (years): 18.0-999.0,  All  Sleep Apnea Register to the social health insurance Referred for a walk test because of claudication Maximal walking ditance < 750m Older than 18 years old Able to understand the protocol of the study  Cardiac insufficiency already known, stage III or IV i.e. dyspnea at rest Unstable angina or myocardial infarction within the previous three months Severe reparatory disease already known Parkinson disease, hémiplégia ou paraplégia Does not want to participate to the protocol Pregnant women Adults to enhanced protection, deprived of their liberty by judicial or administrative authority, without consent hospitalized or admitted to a health facility or social purposes other than research Being in a period of from another biomedical study


eligible ages (years): 50.0-999.0,  All  Osteoarthritis Cardiovascular Risk Factors Cardiovascular Disease Metabolic Syndrome Patients referred for symptomatic hand or knee osteoarthritis All patients referred in the same period for soft tissue disease > 50 years old  Any other rheumatologic condition secondary osteoarthritis


eligible ages (years): 0.0-999.0,  All  Peripheral Arterial Disease a positive history of chronic claudication exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon an ankle/brachial index < 0.90 at rest  absence of Peripheral Arterial Disease (PAD) acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma exercise capacity limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology


eligible ages (years): 20.0-75.0,  All  High Risk Cardiovascular Disease Patients high risk hypertension patients a. eGFR > 60 with one of target organ damages b. eGFR <= 60 diabetes mellitus with microalbumin ration (AC ratio >= 30mg/g) anuric ESRD patients on dialysis the relatives of acute myocardial infarction patients under 55 years old (men)/ 65 years old (women)  acute myocardial infarction, acute coronary syndrome patients, symptomatic coronary artery disease or history of these diseases symptomatic peripheral artery disease, heart failure and history of these diseases desired life time under 6 months due to non-cardiovascular disease (e.g. cancer, sepsis) women with pregnancy or on nursing history of contrast allergy and related side effects


eligible ages (years): 18.0-999.0,  All  Peripheral Arterial Disease Critical Limb Ischemia Intermittent Claudication All adults > 18 years old willing to be randomized Symptomatic PAD (critical limb ischemia or intermittent claudication) caused by >50% stenosis or occlusion of infrainguinal arteries and eligible for endovascular treatment according to established indications  Acute thromboembolic disease in the leg Infrainguinal aneurysmal disease Previous participation in the study or in other randomised interventional study of infrainguinal lesions Patients without a Swedish personal identification number


eligible ages (years): 18.0-65.0,  All  Hypertension The final selection of the sample of 80 patients diagnosed with stage I arterial hypertension will be based on the ABPM results (24h SBP/DBP ≥ 130/80 mm Hg)  Patients who present with normal ABPM values at the end of the 3-month period will be excluded from the study. Subjects diagnosed with white-coat hypertension [increased office BP values (SBP/DBP ≥ 140/90 mm Hg) combined with normal ABPM values (24h SBP/DBP < 130/80 mm Hg)] will also be excluded from the study All subjects with contra-indications for submission of drugs used in the research protocol are going to be excluded from the study. The following categories of patients will not participate in the research: renal failure, hepatic failure, renal artery stenosis, bronchial asthma, vasoconstrictive (Prinzmetal's) angina, hypertrophic cardiomyopathy, aortic valve stenosis, mitral valve stenosis, sinus tachycardia, sinus bradycardia, sick sinus syndrome, Wolff-Parkinson-White syndrome, chronic atrial fibrillation, second and third degree atrioventricular block, right heart failure due to pulmonary hypertension, pheochromocytoma, peripheral artery disease. Pregnant and nursing women will be excluded from the study (history and pregnancy test)


eligible ages (years): 18.0-999.0,  All  Abdominal Aortic Aneurysm Carotid Atherosclerosis Critical Lower Limb Ischaemia Age greater than 18 years Patient willing to give full informed consent for participation Patients undergoing elective carotid endarterectomy or Patients undergoing open abdominal aortic aneurysm repair or Patients undergoing endovascular abdominal aneurysm repair or Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)  Pregnancy Significant upper limb peripheral arterial disease Previous history of upper limb deep vein thrombosis Patients on glibenclamide or nicorandil (these medications may interfere with RIPC) Patients with an estimated pre-operative glomerular filtration rate < 30mls/min/1.73m2 Patients with a known history of myocarditis, pericarditis or amyloidosis Patients with an estimated pre-operative glomerular filtration rate < 30mls/min/1.73m2 Patients with severe hepatic disease defined as an international normalised ratio >2 in the absence of systemic anticoagulation Patients with severe respiratory disease (for the trial, defined as patients requiring home oxygen therapy) Patients previously enrolled in the trial representing for a further procedure Patients with previous axillary surgery


eligible ages (years): 0.0-999.0,  All  Peripheral Arterial Disease, Rutherford Stage 4 and 5 With the Possibility to Improve Vascularization. Patients with peripheral arterial disease Rutherford stage 4 and 5, where it is possible to improve the vascularization of the affected leg with the help of an endovascular and / or open surgical vascular intervention Patients with both legs are affected, but the most severe leg does not exceed stage 5  Severe cardiopulmonary comorbidity (NYHA 4) and previous amputations of lower leg or thigh Patients with limited amputation of the toes can participate Insufficient understanding of the Dutch language No physiotherapy insurance


eligible ages (years): 18.0-80.0,  All  ST-Segment Elevation Myocardial Infarction Male or non-pregnant female Age ≥ 18 years old and ＜80 years old Consecutive patients who should be hospitalized with documented evidence of ST-Segment Elevation Myocardial Infarction receiving Percutaneous Coronary Intervention All patients havepersistent≥0.2 Millivolt ST segment elevation in two or more contiguous precordial leads or ≥0.1 Millivolt ST elevation in two or more contiguous limb leads, with one of the following: persistent chest pain or elevatory of biomarkers of myocardial necrosis Time from chest pain onset to receiving Percutaneous Coronary Intervention <12 hours Persistent chest pain <12 hours Provision of informed consent prior to any study specific procedures  Involved in other trials In recent one year have P 2 Y 12 receptor antagonist drug treatment history or long-term use of immunosuppressive agents Recurrent myocardial infarction or previous history of Coronary Artery Bypass Graft(CABG) surgery or rescue Percutaneous Coronary Intervention Active bleeding or bleeding history With obvious infection and body temperature (axillary temperature) higher than 38.0 ℃ Autoimmune diseases Malignancies In recent 6 months have received major surgery Left ventricular ejection fraction is less than 30% Life expectancy less than one year


eligible ages (years): 18.0-75.0,  All  Dilated Cardiomyopathy established diagnosis of non-ischemic dilated cardiomyopathy EF < 35% NYHA f.c. II Optimal medical management > 6 months Age < 75 years and > 18 years  known hypersensitivity to the medication age > 75 years or < 18 years EF > 35% renal insufficiency (GF < 30) liver dysfunction (liver tests > 3x the upper normal limit)) LQT syndrome drugs that affect CYP3A4 metabolism (azoles, macrolides, calcineurin inhibitors etc.) dementia active hemathological or malignant disease


eligible ages (years): 18.0-90.0,  All  Peripheral Arterial Disease General Signed informed consent At least 18 years old Documented symptomatic iliac, femoropopliteal (FP) or below-the knee artery (BTK) atherosclerotic disease (Rutherford/Becker category 2, 3 or ≥4) Undergone clinically indicated uncomplicated endovascular intervention to one or more locations of the iliac, femoropopliteal below-the knee arteries Estimated survival ≥1 year in the judgment of the primary operator Pre-index procedure use of ASA, clopidogrel or both at any dose Angiographic De novo or restenotic lesions in the common and/or external iliac artery, superficial femoral artery (SFA), popliteal artery, tibio-peroneal (TP) trunk, anterior tibial (AT) artery, peroneal artery (PA) or posterior tibial (PT) artery (applies to all target lesions if multiple) Subjects with multiple planned procedures can be enrolled after the completion of the last planned procedure.-  General Complicated qualifying procedure (perforation, flow limiting dissection, distal embolization requiring re-intervention, need for repeat endovascular, surgical revascularization, amputation or blood transfusion prior to hospital discharge following an index procedure Extended hospital stay >7 days following the index procedure Allergy to aspirin or clopidogrel MI or percutaneous coronary intervention with drug eluting stents within the past 9 months Life expectancy less than 12 months due to other medical co-morbid condition(s) that could limit the subject's ability to participate in the trial, limit the subject's compliance with the follow-up requirements, or impact the scientific integrity of the trial Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated Intolerance to antiplatelet, anticoagulant, or thrombolytic medications Platelet count <90,000 mm3 or >600,000 mm3 Serum creatinine >2.5 mg/dL


eligible ages (years): 0.0-999.0,  All  Peripheral Arterial Disease (PAD) Symptomatic peripheral arterial disease (PAD) involving the above-the-knee femoropopliteal arteries


eligible ages (years): 18.0-999.0,  All  Peripheral Arterial Diseases Known moderate PVD New claudication patient with Rutherford stage 2 and Fontaine stage 2a symptoms  Known upper limb PVD Severe cardiac condition Risk classification for exercise training: class C and above Severe respiratory condition Previous history of upper limb deep vein thrombosis Patients on glibenclamide or nicorandil May affect RIPC Raynaud's Disease Contra indications for MRA Pregnancy


eligible ages (years): 18.0-999.0,  All  Peripheral Vascular Diseases Patients planned for lower limb Angioplasty  Known upper limb PVD Previous history of upper limb deep vein thrombosis Patients on glibenclamide or nicorandil May affect RIPC Raynaud's Disease Intra operative decision to use graft will be documented


eligible ages (years): 18.0-75.0,  All  Painful Diabetic Neuropathy Diabetic Neuropathy, Painful Age ≥ 18 years to 75 years Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral medication and / or insulin No significant changes anticipated in diabetes medication regimen No new symptoms associated with diabetes within the last 3 months prior to study entry Diagnosis of painful diabetic peripheral neuropathy in both lower extremities Lower extremity pain for at least 6 months Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain mm very severe pain) Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference between legs at Initial Screening The average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2  Peripheral neuropathy caused by condition other than diabetes Other pain more severe than neuropathic pain that would prevent assessment of DPN Progressive or degenerative neurological disorder Myopathy Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease) Active infection Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) Positive HIV or HTLV at Screening Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening Subjects with known immunosuppression or currently receiving immunosuppressive drugs, chemotherapy or radiation therapy


eligible ages (years): 50.0-999.0,  All  Myocardial Ischemia Surgery written informed consent intermedial and high risk non cardiac surgery general anesthesia ongoing or recently suspended antiplatelet therapy  pregnancy planned locoregional anesthesia without general anesthesia unstable or ongoing angina recent (< 1 month) or ongoing acute myocardial infarction in other randomised controlled studies in the previous 30 days peripheral vascular disease affecting the upper limbs cardiac surgery


eligible ages (years): 18.0-999.0,  All  Peripheral Arterial Disease Venous Insufficiency Patient suffering from a PAD (systolic pressure index ≥ 0,60 and ≤ 0,75) and having moderate venous insufficiency or classified as C1s to C4 using the CEAP classification Age over 18 years French health insurance Signed informed consent  Hypertension not controlled or hypertensive crisis (risk of non reproducibility of SPI and TBI) Diabetes Mediacalcosis (SPI not computable) Inflammatory arterial diseases of the lower limb Permanent edema, lipedema and lymphedema Wound and fragile skin Phlegmatia coerulea dolens Septic thrombophlebitis Severe coronary artery disease Oozing and infectious skin diseases, skin ulcers


eligible ages (years): 18.0-999.0,  All  Congenital Heart Disease Male or Female over 18 years of age Moderate or Complex Congenital Heart Disease Willingness to Consent  Pregnancy Surgery within 6 months Unrepaired cyanotic heart disease Patients with Eisenmenger Syndrome physiology


eligible ages (years): 18.0-999.0,  All  Intermittent Claudication Peripheral Vascular Disease All ethnic groups, male or female above the age of 18 years Diagnosis of mild intermittent claudication Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device Blood pressure currently under moderate control (< 160/100mmHg) No current foot ulceration  Patients meeting any of the following are to be excluded Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol Has diabetes Ankle Brachial Pressure Index > 0.9 Has any metal implants Pregnant Has a cardiac pacemaker or defibrillator device Has recent lower limb injury or lower back pain Has current foot ulceration or other skin ulcers Has foot deformities


eligible ages (years): 21.0-999.0,  All  Remote Ischaemic Preconditioning Contrast Induced Nephropathy Elective intra-arterial peripheral angiography/angioplasty Patients >21 years of age Patients with CKD as evidenced by eGFR levels of 30ml/min < eGFR < 60ml/min (moderate risk) or eGFR levels of >= 60ml/min (low risk)  Severe renal impairment eGFR <30ml/min Evidence of acute renal failure or patients on dialysis History of previous CIN Contraindication to volume replacement therapy Pregnancy Patients on glibenclamide or nicorandil (these medications may interfere with RIPC)


A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

eligible ages (years): 4.0-12.0,  All  Obsessive-Compulsive Disorder OCD Participants (N = 72) Aged 4-12 years and living within a four-hour commute from NIH Currently meet DSM-IV for OCD Recent onset of symptoms (less than 6 months.) Healthy Controls (N = 60-72) Age and sex matched to ODC participants Must be free of current or past psychopathology  OCD Participants Diagnosis of schizophrenia, schizoaffective, bipolar, delusional, or psychotic disorder; autistic spectrum disorder or pervasive developmental disorder; neurologic disorder other than tics; or rheumatic fever Significant or unstable medical illness Full scale IQ less than 80 Healthy Controls Full scale IQ less than 80 Significant or unstable medical illness


eligible ages (years): 0.0-999.0,  All  Coronary Arteriosclerosis Adults older than 21 years Coronary artery disease established by angiography No myocardial infarction within 1 month Left ventricular ejection fraction greater than 30% No congestive heart failure symptoms within 2 months No medical condition that might prohibit safe participation in cardiac rehabilitation Subject understands protocol and provides written, informed consent in addition to willingness to comply with specified follow-up evaluations  Significant structural heart disease (e.g. hypertrophic or dilated cardiomyopathy, valvular heart disease) as determined by echocardiography Angina pectoris that is prolonged in duration (greater than 20 minutes), or does not respond to nitroglycerin (2 tablets) Subject physically unable to perform cardiac rehabilitation protocol due to neurologic or orthopedic conditions Hypersensitivity to organic nitrates Women of childbearing age unless recent pregnancy test is negative Lactating women Known hypersensitivity to dipyridamole or to gadolinium if patient eligible for MRI study


eligible ages (years): 0.5-12.0,  All  Pharyngitis Give informed consent, assent, and documentation of patient authorization for disclosure of study results Since all patients are below the legal age of consent, assent from the patient must be obtained (as applicable following state regulations) and written informed consent obtained from the parent or legal guardian Age > = 6 months -12 years A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the clinical signs and symptoms compatible with tonsillitis and/or pharyngitis, including sore throat or difficulty feeding or swallowing or irritability that suggests the presence of a sore throat with at least one of the following Tonsillar or pharyngeal exudate Tender cervical lymph nodes Fever or history of fever treated with antipyretics Odynophagia Uvular edema Pharyngeal Erythema of moderate or greater intensity  Chronic or recurrent (two weeks duration two times per year) odynophagia or enlarged tonsils secondary to viral or proven bacterial etiology The need for hospitalization or I.V. antimicrobial therapy Pharyngitis known or suspected to be due to a pathogen resistant to beta-lactam antimicrobials Patients who are known carriers of S. pyogenes Previous allergy, serious adverse reaction to, or intolerance to, penicillin or any other member of the beta-lactam class of antimicrobials Any serious illness or concomitant condition that the investigator judges would preclude the study evaluations or make it unlikely that the course of study therapy and follow-up could be completed. This would also Any rapidly progressive underlying disease with a shortened life expectancy The inability to swallow the study dosage form Unable to understand the requirements of the study Neutropenia (<1000 PMNs/mm3) or other known immunocompromised state


eligible ages (years): 4.0-16.0,  All  Kawasaki Disease Males or females between 4 and 16 Meet the epidemiological definition of Kawasaki Disease or have a diagnosis of incomplete KD, including evidence of coronary artery disease as determined by their physician Be able to exercise adequately to achieve 85% age predicted maximum heart rate  Terminal illness where expected survival is < 6 months


eligible ages (years): 5.0-16.0,  All  Learning Disorders Child Behavior Disorders DSM-IV Axis II diagnosis of mental retardation behavioural and family therapy tried for 6 months but has failed in school, at least part time score of >=8 on hostility scale subject is otherwise healthy  Patients with a seizure disorder requiring repeated change of medication extrapyramidal symptoms not well controlled by medication abnormal and clinically significant electrocardiogram (ECG) changes history of tardive dyskinesia (a condition of uncontrollable movements of the tongue, lips, face, trunk, hands and feet that is seen in patients receiving long-term medication with certain types of antipsychotic drugs), or neuroleptic malignant syndrome (a rare condition in patients receiving antipsychotic medication in which patients may develop fever, sweating, unstable blood pressure, rigid muscles, and other symptoms, including changes in their normal mental state) known hypersensitivity to antipsychotic medications, including risperidone


eligible ages (years): 0.0-18.0,  All  Kawasaki Disease To be eligible for the trial, subjects must meet all of the following All eligible subjects, or legal representative, must provide written informed consent/assent, prior to initiation of any study procedure Eligible subjects will be infants and children, under 18 years old, with acute KD who remain or become febrile (>/= 38.3˚ C or 101.0˚ F) after the end of the 48 h-period after completing their IVIG infusion (2gm/kg) Patients must have persistent or reoccurrence of fever > 48 hours of observation to be eligible for the trial Prior to the initial IVIG treatment, patients must have been febrile for >/= 3 days and have met 4/5 standard clinical (Table 1) patients with fever and 3/5 clinical will be eligible if echocardiogram demonstrates at least one coronary artery segment with a Z score of > 2 Patients must present for their initial diagnosis and IVIG treatment within the first 14 days after fever onset (Illness Day 14) Females of childbearing potential and males must be using adequate contraception (abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) throughout the trial All eligible subjects must have a chest radiograph within one week prior to first infusion of study drug with no evidence of malignancy, infection or fibrosis  If a subject has any of the following he or she may not be enrolled in the study Have been receiving corticosteroids (ie, via any route) at doses > 1 mg/kg prednisone equivalent daily Have history of TB or TB exposure Have history of histoplasmosis or coccidiomycosis Have received anakinra (Kineret®), etanercept (Enbrel®), or adalimumab (Humira®) within 1 month prior to first study drug administration Have any chronic disease, except asthma, atopic dermatitis or controlled seizure disorder Have documented history of current active hepatitis B or a history of hepatitis C infection Have documented history of human immunodeficiency virus (HIV) infection Have received a transplanted organ (with the exception of a corneal transplant performed > 3 months prior to first study drug administration) Have a known malignancy or history of malignancy within the 5-year period prior to first study drug administration (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence)


eligible ages (years): 8.0-25.0,  All  Kawasaki Disease History of Kawasaki disease more than 12 months before enrollment Present age of 8 years or older  Diabetes mellitus Not controlled hypertension Treatment with drugs thay modify endothelial function such as angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers Smokers of more than 5 cigarettes per day Total cholesterol higher than 250 mg/dl Triglycerides higher than 300mg/dl Chronic treatment with statins Chronic renal insufficiency (creatinine > 1.5 mg/dl)


eligible ages (years): 0.0-90.0,  All  Burn Ages 0-90 years Any patient admitted to the hospital with burn injury requiring grafting and a donor site  Patient with severe burn injuries expected to die


eligible ages (years): 18.0-50.0,  All  Allergic Rhinitis Ability to understand and provide informed consent Male or Female (non-pregnant), age 18-50 Females must be: Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral tubal ligation), OR postmenopausal (at least 1 year since last menses), OR using a medically acceptable form of birth control throughout the duration of the study Clinical history of seasonal or perennial allergic rhinitis for at least two years, with or without mild persistent asthma Positive puncture skin test greater than or equal to 5 mm diluent control Positive CAP-RAST to Fel d 1 > 0.35 kU/L Positive intranasal cat allergen challenge as defined by > 5 sneezes or a tripling of measured nasal lavage mediators In vitro assay of basophil responsiveness to cat allergen with greater than 20% histamine release The use of antihistamines, cromolyns, leukotriene modifiers and other non-steroid (astelin and topical decongestants), nasal medications will be allowed, but they will be withheld for 5 days prior to each nasal allergen provocation session. Inhaled corticosteroids for mild asthma will be permissible No known contraindications to therapy with omalizumab  Asthma with FEV1 < 80%, moderate to severe asthma classification per NAEP Standards (1997 National Asthma Education and Prevention Program Expert Panel Report II guidelines) Serum IgE levels less than 30 IU/mL or greater than 700 IU/mL at the time of enrollment will be excluded Unexplained elevation of ESR, hematocrit < 32%, WBC count 2400/microliter lower limit of normal, platelet < 75000/microliter, creatinine > 141.4 micromolar/L, or AST > 100 IU/L Body weight less than 30 kg or greater than 150 kg will be excluded Plans to become pregnant or breastfeed will be excluded from the study A perforated nasal septum, structural nasal defect, large nasal polyps causing obstruction, evidence of acute or chronic sinusitis A life expectancy less than 6 months A terminal illness as determined by the investigator A history of malignancy, anaphylaxis or bleeding disorder are also illnesses Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements


eligible ages (years): 2.0-12.0,  All  Tonsillitis Patients who had evidence of acute pharyngitis/tonsillitis based on erythematous pharyngeal mucosa or thick exudate covering the pharynx and tonsillar area, and at least one of the following signs or symptoms were included: sore/scratchy throat; pain on swallowing; chills and/or fever cervical adenopathy; scarlet fever rash on the face and skin folds, or red tongue with prominent papillae ("strawberry tongue"). Subjects were required to have a positive rapid antigen detection test (RADT) or a positive culture of the pharynx or tonsils for GABHS  Patients were excluded if they had previously diagnosed disease(s) of immune function or treatment with any systemic antibiotic within the previous 7 days


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) and in accordance with local guidelines Patients eligible to anti-TNF therapy Patients naïve to anti-TNFa drugs Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form  Patients with tumors Patients already included in clinical trials


eligible ages (years): 0.167-20.0,  All  Mucocutaneous Lymph Node Syndrome Kawasaki Disease Male Age 2 months to 20 years of age Female Age 2 months to 11 years of age Provision of Parental Consent Kawasaki Disease Presentation  Laboratory Any laboratory toxicity, at the time of the screening visit or at any time during the study that in the opinion of the Investigator would preclude participation in the study or Platelet count < 100,000/mm3 WBC count < 3,000 cells/mm3 Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal for the Lab Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit Female subjects diagnosed with KD 12 years of age and older Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept Prior or concurrent cyclophosphamide therapy Prior treatment with any TNF alpha antagonist or steroid within 48 hours prior to initiation of IVIG Concurrent sulfasalazine therapy


eligible ages (years): 0.0-999.0,  All  Hypertension Hypertensive patients who have never taken Micombi Tablets


eligible ages (years): 50.0-999.0,  All  Hypercholesterolemia Type 2 Diabetes Hypertension Patients meeting the following will be included in the study Patients giving voluntary written consent to participate in the study Male or female patients 50 years of age or older (at informed consent) Hypercholesterolemia patients (Untreated patients: LDL-C level ≥140 mg/dL; treated patients: LDL-C level ≥120 mg/dL) Type 2 diabetes patients (HbA1c level ≥6.1% (JDS criteria), with or without history of drug therapy) Hypertension patients (SBP ≥130 mmHg or DBP ≥80 mmHg, with or without history of drug therapy) Patients with two or more of the following risk factors Male years of age or older Smoker  Patients meeting the following will be excluded from the study Patients receiving rosuvastatin, pitavastatin, or atorvastatin therapy within one month prior to informed consent Patients judged to have familial hypercholesterolemia Patients with a serum triglyceride level of ≥400 mg/dL Patients with a history of myocardial infarction Patients with a history of coronary revascularization (PCI or CABG) Patients with a history of treatment of unstable angina Patients with a history of cerebrovascular accident (excluding asymptomatic lacunar infarction) Heart failure patients Patients with a history of hypersensitivity to statins


eligible ages (years): 18.0-999.0,  All  Psoriatic Arthritis Males or females, aged ≥ 18 years at time of consent Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration Meet the Classification for Psoriatic Arthritis (CASPAR) for PsA at time of screening Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs) May not have axial involvement alone Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine Have ≥ 3 swollen AND ≥ 3 tender joints Males & Females must use contraception Stable dose of NSAIDs, narcotics and low dose oral corticosteroids allowed Have at least one ≥2 cm psoriasis lesion  Pregnant or breast feeding History of allergy to any component of the investigational product Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker


eligible ages (years): 0.5-11.0,  All  Rhinitis Perennial Aged 6 months through 11 years Patients with perennial allergic rhinitis  Neither serum specific IgE antibody or skin reaction is positive for the antigen of perennial allergy Nasal symptom score is 0 for either sneezing or nasal discharge, or sum of these two score is less than 3, or nasal congestion score is 4 Patients with vasomotor rhinitis or eosinophilic rhinitis